This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Recurrent miscarriage: diabetes drug could ... An existing drug can be used to improve the womb for pregnancy, ... (08 Jan 2020)
Nerve Stimulation May Benefit Women with ... A treatment involving electrical nerve stimulation helped women ... (08 Jan 2020)
Cancer drugs could potentially treat COPD, ... New research from the University of Sheffield shows a certain ... (08 Jan 2020)
Tea drinkers live longer Drinking tea at least three times a week is linked with a longer ... (08 Jan 2020)

PDE5 Inhibitors do not increase risk of melanoma

pd5iUsing drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association.
Last year, a research team from Harvard University in Boston, United States, reported that Viagra, a phosphodiesterase inhibitor (PDEi) drug used against impotence, increased the risk of malignant melanoma of the skin. It was interpreted as if Viagra stimulated the growth of melanoma cells.
Researchers from Umeå University, in collaboration with researchers in Uppsala, Lund and New York, now publish a study in JAMA (Journal of the American Medical Association) (JAMA) contradicting those findings.
“Our research shows that already collecting one single prescription of a PDEi drug, such as Viagra, Cialis or Levitra, was linked with a statistically significant increased risk of melanoma; something that speaks against a biological connection,” says Pär Stattin, Professor of Urology at Umeå University, who led the investigation.
The study also shows that the risk was highest for early, superficial melanoma, which is yet another aspect raising questions about a causal association between the use of PDEi and melanoma. Furthermore, the results show that men who received prescriptions for PDEi were healthier, had higher education and higher income than other men, which is not surprising given that these drugs are paid out of pocket in contrast to most other drugs in Sweden. The study was 30 times larger than the American study and was conducted using data from the Swedish Prescribed Drug Register, the Swedish Melanoma Register, and other health care registers and demographic databases in Sweden.
“Our results speak against that drugs for impotence increase the risk of melanoma. Data rather suggest that men using Viagra, Cialis and Levitra tend to sunbathe more, are more health-conscious and more often seek medical care for skin moles; leading to a higher risk of a melanoma diagnosis. The most important risk factor for melanoma is exposure to strong sunlight, so protection against UV exposure remains the cornerstone in melanoma protection,” concludes Pär Stattin.


Source: Umeå universitet

Full bibliographic information:
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma, Journal of the American Medical Association, JAMA, 2015;313(24):1-7. DOI:10.1001/jama.2015.6604 Read the study in JAMA

Highlights

  • Give a Gift this Christmas which gives back

    The story of medicine is the story of civilization, from an ancient craft of primitive magic and religion to the sophisticated field of science and technology of today.

    Read more...
  • Nescafé 3 in1 LifeCycle HEROES return from South Asia

    Donations for Nescafé 3in1 LifeCycle Challenge 2019 can be sent via sms: 5061 7370 = €2.33; 5061 8920 = €6.99; 5061 9229 = €11.65; or via a call to 5160 2020 = €10, 5170 2005 = €15; and 5180 2006 = €25. Bank details are Swift code VALLMTMT, IBAN number MT 18 VALL 22013000000014814521017, Bank name Bank of Valletta, Account number 14814521017.

    Read more...

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…